Drug
BGB-11417
BGB-11417 is a pharmaceutical drug with 5 clinical trials. Currently 5 active trials ongoing.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
5(100%)
Phase Distribution
Ph phase_1
3
60%
Ph phase_2
2
40%
Phase Distribution
3
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
2(40.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
5
trials recruiting
Total Trials
5
all time
Status Distribution
Active(5)
Detailed Status
Active, not recruiting3
Recruiting2
Development Timeline
Analytics
Development Status
Total Trials
5
Active
5
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 13 (60.0%)
Phase 22 (40.0%)
Trials by Status
recruiting240%
active_not_recruiting360%
Recent Activity
5 active trials
Showing 5 of 5
recruitingphase_1
A Study of BGB-11417 in Participants With Myeloid Malignancies
NCT04771130
active_not_recruitingphase_1
Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies
NCT04883957
active_not_recruitingphase_2
Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT05479994
active_not_recruitingphase_1
Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma
NCT05471843
recruitingphase_2
Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL Patients
NCT06463691
Clinical Trials (5)
Showing 5 of 5 trials
NCT04771130Phase 1
A Study of BGB-11417 in Participants With Myeloid Malignancies
NCT04883957Phase 1
Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies
NCT05479994Phase 2
Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT05471843Phase 1
Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma
NCT06463691Phase 2
Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL Patients
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5